AB0043 SERIAL ADMINISTRATION OF RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 AND OSTEOPROTEGERIN-FC ENHANCES THE DIFFERENTIATION OF OSTEOBLASTS

Background Osteoprotegerin (OPG) is an intrinsic antagonist of the RANKL. A recent study reported that RANKL reverse signaling in osteoblasts may prepare for further maturation and vesicular RANK stimulates osteoblast differentiation. Hence, OPG expected to accelerate osteoblastogenesis by affecting signaling. Objectives We compared level differentiation from preosteoblasts serially administrating recombinant human bone morphogenetic protein-2 (rhBMP-2), involved formation regeneration, osteoprotegerin-immunoglobulin Fc segment complex (OPG-Fc), osteoclast inhibitor. Methods The MC3T3-E1 preosteoblast cell line was differentiated one, three, seven days with a treatment OPG-Fc 10–200 ng/mL concentration viability evaluated Cell Counting Kit-8 analysis. cells determined alkaline phosphatase activity. runt domain-containing transcription factor 2 (Runx2) osteopontin (OPN) manifestation, differentiation, examined real-time polymerase chain reaction western blotting. Results During high one-day using 100 OPG-Fc. 50 rhBMP-2 days, followed produced highest level, which approximately 5.3 times control group (P < 0.05). expression Runx2 mRNA significantly increased, reaching 2.5 under condition seven-day 0.001). protein increased 5.7 rhBMP-2, 0.01). OPN showed no change various conditions combinations. Conclusion Differentiation ability strong serial levels increased. These results imply combination efficacy. Reference [1]Ikebuchi Y, Aoki S, Honma M, et al. (2018) Coupling resorption signalling. Nature. 561, 195-200. Acknowledgements: NIL. Disclosure Interests None Declared.